Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 57Carcinoma, Hepatocellular 45Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Lung Neoplasms 10Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Esophageal Neoplasms 9Advanced Gastric Cancer 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Liver Neoplasms 5Glioma 5Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

Gemcitabine 3Cisplatin 2durvalumab 1camrelizumab 1apatinib 1Tegafur 1Surgical Procedures, Operative 1Simvastatin 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Biliary Tract Carcinoma × apatinib × Clear all
NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

First Affiliated Hospital of Zhejiang University

Phase 2 Active not recruiting
30 enrolled
Gastrointestinal

Advanced Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡